nach oben

Familial Cancer

Erschienen in:

01.12.2010

The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers

verfasst von: Ana Cristina Vargas, Leonard Da Silva, Sunil R. Lakhani

Erschienen in: Familial Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

BRCA1 and BRCA2 associated breast cancer comprises a small but important group of hereditary breast cancer. Testing for BRCA1 and BRCA2 has significant clinical and personal implications for the patients in terms of therapy and follow-up of individual family members. The sequencing of the genes is expensive and since the information derived may have a profound effect on the individual and family members, it is important that testing is done only when the risk of carrying a mutation is thought to be high. Over the last decade, researchers have developed a number of statistical models for predicting risk for harboring mutations in these genes and the risk of subsequently developing breast and ovarian cancer. These models usually take into account the type of tumor and age at occurrence as well as family history. Data from pathological analysis show that although breast tumours are heterogeneous, there are histological characteristics that are seen more frequently in carriers of BRCA1 germ line mutations compared to BRCA2 and sporadic breast cancers. A number of authors have suggested that the addition of pathological data to risk algorithms may improve the predictive power of these models and provide a more accurate way of identifying individuals who may benefit from testing. Here we review the pathology of familial breast cancer and assess the evidence to justify the use of pathology in refining risk assessment models.

Thompson D, Easton DF (2002) Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365PubMed

Wooster R, Weber BL (2003) Breast and ovarian cancer. N Engl J Med 348(23):2339–2347CrossRefPubMed

Venkitaraman AR (2002) Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108(2):171–182CrossRefPubMed

Balleine RL, Murali R, Bilous AM et al (2006) Histopathological features of breast cancer in carriers of ATM gene variants. Histopathology 49(5):523–532CrossRefPubMed

Cybulski C, Huzarski T, Byrski T et al (2009) Estrogen receptor status in CHEK2-positive breast cancers: implications for chemoprevention. Clin Genet 75(1):72–78CrossRefPubMed

Domchek SM, Eisen A, Calzone K, Stopfer J, Blackwood A, Weber BL (2003) Application of breast cancer risk prediction models in clinical practice. J Clin Oncol 21(4):593–601CrossRefPubMed

Weitzel JN, Lagos VI, Cullinane CA et al (2007) Limited family structure and BRCA gene mutation status in single cases of breast cancer. JAMA 297(23):2587–2595CrossRefPubMed

Huo D, Senie RT, Daly M et al (2009) Prediction of BRCA mutations using the BRCAPRO model in clinic-based African American, hispanic, and other minority families in the United States. J Clin Oncol 27(8):1184–1190CrossRefPubMed

James PA, Harris M, Lindeman GJ, Mitchell G (2008) Towards more effective and equitable genetic testing for BRCA1 and BRCA2 mutation carriers. J Med Genet 45(11):765–766CrossRefPubMed

10.

Parmigiani G, Chen S, Iversen ES Jr et al (2007) Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med 147(7):441–450PubMed

11.

Kurian AW, Gong GD, John EM et al (2009) Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California breast cancer family registry. Cancer Epidemiol Biomarkers Prev 18(4):1084–1091CrossRefPubMed

12.

Shannon KM, Lubratovich ML, Finkelstein DM, Smith BL, Powell SN, Seiden MV (2002) Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center. Cancer 94(2):305–313CrossRefPubMed

13.

Frank TS, Deffenbaugh AM, Reid JE et al (2002) Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20(6):1480–1490CrossRefPubMed

14.

Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 72(5):1117–1130CrossRefPubMed

15.

Struewing JP, Watson P, Easton DF, Ponder BA, Lynch HT, Tucker MA (1995) Prophylactic oophorectomy in inherited breast/ovarian cancer families. J Natl Cancer Inst Monogr (17): 33–35

16.

Rebbeck TR, Levin AM, Eisen A et al (1999) Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91(17):1475–1479CrossRefPubMed

17.

Hartmann LC, Sellers TA, Schaid DJ et al (2001) Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93(21):1633–1637CrossRefPubMed

18.

Meijers-Heijboer H, van Geel B, van Putten WL et al (2001) Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345(3):159–164CrossRefPubMed

19.

Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346(21):1609–1615CrossRefPubMed

20.

Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol 22(6):1055–1062CrossRefPubMed

21.

Couch FJ, DeShano ML, Blackwood MA et al (1997) BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer. N Engl J Med 336(20):1409–1415CrossRefPubMed

22.

Parmigiani G, Berry D, Aguilar O (1998) Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet 62(1):145–158CrossRefPubMed

23.

Berry DA, Iversen ES Jr, Gudbjartsson DF et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20(11):2701–2712CrossRefPubMed

24.

Evans DG, Eccles DM, Rahman N et al (2004) A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO. J Med Genet 41(6):474–480CrossRefPubMed

25.

Antoniou AC, Cunningham AP, Peto J et al (2008) The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions. Br J Cancer 98(8):1457–1466CrossRefPubMed

26.

Tyrer J, Duffy SW, Cuzick J (2004) A breast cancer prediction model incorporating familial and personal risk factors. Stat Med 23(7):1111–1130CrossRefPubMed

27.

Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E (1997) Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89(3):227–238CrossRefPubMed

28.

Calzone KA, Stopfer J, Blackwood A, Weber BL (1997) Establishing a cancer risk evaluation program. Cancer Pract 5(4):228–233PubMed

29.

Frank TS, Manley SA, Olopade OI et al (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16(7):2417–2425PubMed

30.

Anderson H, Bladstrom A, Olsson H, Moller TR (2000) Familial breast and ovarian cancer: a Swedish population-based register study. Am J Epidemiol 152(12):1154–1163CrossRefPubMed

31.

Antoniou AC, Pharoah PP, Smith P, Easton DF (2004) The BOADICEA model of genetic susceptibility to breast and ovarian cancer. Br J Cancer 91(8):1580–1590PubMed

32.

Evans DG, Lalloo F, Wallace A, Rahman N (2005) Update on the manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 42(7):e39CrossRefPubMed

33.

Evans DG, Lalloo F, Cramer A et al (2009) Addition of pathology and biomarker information significantly improves the performance of the manchester scoring system for BRCA1 and BRCA2 testing. J Med Genet 46(12):811–817CrossRefPubMed

34.

Antoniou AC, Hardy R, Walker L et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, myriad and the manchester scoring system using data from UK genetics clinics. J Med Genet 45(7):425–431CrossRefPubMed

35.

Lakhani SR, Gusterson BA, Jacquemier J et al (2000) The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 6(3):782–789PubMed

36.

Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90(15):1138–1145CrossRefPubMed

37.

Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H et al (2006) Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping. Clin Cancer Res 12(6):1693–1700CrossRefPubMed

38.

Sensi E, Tancredi M, Aretini P et al (2003) p53 inactivation is a rare event in familial breast tumors negative for BRCA1 and BRCA2 mutations. Breast Cancer Res Treat 82(1):1–9CrossRefPubMed

39.

Lakhani SR, Van De Vijver MJ, Jacquemier J et al (2002) The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol 20(9):2310–2318CrossRefPubMed

40.

Palacios J, Honrado E, Osorio A et al (2003) Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 9(10 Pt 1):3606–3614PubMed

41.

Honrado E, Osorio A, Milne RL et al (2007) Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 20(12):1298–1306CrossRefPubMed

42.

Lakhani SR, Reis-Filho JS, Fulford L et al (2005) Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 11(14):5175–5180CrossRefPubMed

43.

Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64(3):830–835CrossRefPubMed

44.

Armes JE, Venter DJ (2002) The pathology of inherited breast cancer. Pathology 34(4):309–314CrossRefPubMed

45.

Pinilla SM, Honrado E, Hardisson D, Benitez J, Palacios J (2006) Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. Breast Cancer Res Treat 99(1):85–90CrossRefPubMed

46.

Rakha EA, Elsheikh SE, Aleskandarany MA et al (2009) Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res 15(7):2302–2310CrossRefPubMed

47.

Weber F, Fukino K, Sawada T et al (2005) Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer 92(10):1922–1926CrossRefPubMed

48.

Honrado E, Osorio A, Palacios J, Benitez J (2006) Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. Oncogene 25(43):5837–5845CrossRefPubMed

49.

Lidereau R, Eisinger F, Champeme MH et al (2000) Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 60(5):1206–1210PubMed

50.

Chang J, Hilsenbeck SG, Sng JH, Wong J, Ragu GC (2001) Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. Clin Cancer Res 7(6):1739–1742PubMed

51.

Cortesi L, Turchetti D, Bertoni C et al (2000) Comparison between genotype and phenotype identifies a high-risk population carrying BRCA1 mutations. Genes Chromosomes Cancer 27(2):130–135CrossRefPubMed

52.

Farshid G, Balleine RL, Cummings M, Waring P (2006) Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing. Am J Surg Pathol 30(11):1357–1366CrossRefPubMed

53.

Eisinger F, Nogues C, Guinebretiere JM et al (1999) Novel indications for BRCA1 screening using individual clinical and morphological features. Int J Cancer 84(3):263–267CrossRefPubMed

54.

Young SR, Pilarski RT, Donenberg T et al (2009) The prevalence of BRCA1 mutations among young women with triple-negative breast cancer. BMC Cancer 9:86CrossRefPubMed

55.

Arnes JB, Brunet JS, Stefansson I et al (2005) Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer. Clin Cancer Res 11(11):4003–4011CrossRefPubMed

56.

Collins LC, Martyniak A, Kandel MJ et al (2009) Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol 33(7):1093–1097CrossRefPubMed

57.

Phillips KA, Nichol K, Ozcelik H et al (1999) Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. J Natl Cancer Inst 91(5):469–473CrossRefPubMed

58.

Crook T, Brooks LA, Crossland S et al (1998) p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17(13):1681–1689CrossRefPubMed

59.

Armes JE, Trute L, White D et al (1999) Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study. Cancer Res 59(8):2011–2017PubMed

60.

Visscher DW, Sarkar FH, Shimoyama RK, Crissman JD (1996) Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Diagn Mol Pathol 5(3):187–193CrossRefPubMed

61.

Holstege H, Joosse SA, van Oostrom CT, Nederlof PM, de Vries A, Jonkers J (2009) High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer. Cancer Res 69(8):3625–3633CrossRefPubMed

62.

Manie E, Vincent-Salomon A, Lehmann-Che J et al (2009) High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors. Cancer Res 69(2):663–671CrossRefPubMed

63.

Xu X, Qiao W, Linke SP et al (2001) Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat Genet 28(3):266–271CrossRefPubMed

64.

Ongusaha PP, Ouchi T, Kim KT et al (2003) BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest. Oncogene 22(24):3749–3758CrossRefPubMed

65.

Cheung AM, Elia A, Tsao MS et al (2004) Brca2 deficiency does not impair mammary epithelium development but promotes mammary adenocarcinoma formation in p53(+/−) mutant mice. Cancer Res 64(6):1959–1965CrossRefPubMed

66.

Palacios J, Honrado E, Osorio A et al (2005) Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 90(1):5–14CrossRefPubMed

67.

van der Groep P, Bouter A, van der Zanden R et al (2006) Distinction between hereditary and sporadic breast cancer on the basis of clinicopathological data. J Clin Pathol 59(6):611–617CrossRefPubMed

68.

Gadzicki D, Schubert A, Fischer C et al (2009) Histopathological criteria and selection algorithms for BRCA1 genetic testing. Cancer Genet Cytogenet 189(2):105–111CrossRefPubMed

69.

Freneaux P, Stoppa-Lyonnet D, Mouret E et al (2000) Low expression of bcl-2 in Brca1-associated breast cancers. Br J Cancer 83(10):1318–1322CrossRefPubMed

70.

Vaziri SA, Tubbs RR, Darlington G, Casey G (2001) Absence of CCND1 gene amplification in breast tumours of BRCA1 mutation carriers. Mol Pathol 54(4):259–263CrossRefPubMed

71.

Rakha EA, El-Sheikh SE, Kandil MA, El-Sayed ME, Green AR, Ellis IO (2008) Expression of BRCA1 protein in breast cancer and its prognostic significance. Hum Pathol 39(6):857–865CrossRefPubMed

72.

Beger C, Pierce LN, Kruger M et al (2001) Identification of Id4 as a regulator of BRCA1 expression by using a ribozyme-library-based inverse genomics approach. Proc Natl Acad Sci U S A 98(1):130–135CrossRefPubMed

73.

Turner NC, Reis-Filho JS, Russell AM et al (2007) BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26(14):2126–2132CrossRefPubMed

74.

Arun B, Vogel KJ, Lopez A et al (2009) High prevalence of preinvasive lesions adjacent to BRCA1/2-associated breast cancers. Cancer Prev Res (Phila Pa) 2(2):122–127

75.

Bane AL, Beck JC, Bleiweiss I et al (2007) BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays. Am J Surg Pathol 31(1):121–128CrossRefPubMed

76.

Simpson PT, Reis-Filho JS, Lambros MB et al (2008) Molecular profiling pleomorphic lobular carcinomas of the breast: evidence for a common molecular genetic pathway with classic lobular carcinomas. J Pathol 215(3):231–244CrossRefPubMed

77.

James PA, Doherty R, Harris M et al (2006) Optimal selection of individuals for BRCA mutation testing: a comparison of available methods. J Clin Oncol 24(4):707–715CrossRefPubMed

78.

Mavaddat N, Rebbeck TR, Lakhani SR, Easton DF, Antonis AC (2010) Incorporating tumour pathology information into breast cancer risk prediction algorithms. Breast Cancer Res 12: R28CrossRefPubMed

79.

Gomez Garcia EB, Oosterwijk JC, Timmermans M et al (2009) A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history. Breast Cancer Res 11(1):R8CrossRefPubMed

80.

Burke W, Petersen G, Lynch P et al (1997) Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer genetics studies consortium. JAMA 277(11):915–919CrossRefPubMed

81.

Pensabene M, Spagnoletti I, Capuano I et al (2009) Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. Ann Oncol 20(5):874–878CrossRefPubMed

82.

Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75(4):535–544CrossRefPubMed

83.

Chenevix-Trench G, Healey S, Lakhani S et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019–2027CrossRefPubMed

84.

Osorio A, Milne RL, Honrado E et al (2007) Classification of missense variants of unknown significance in BRCA1 based on clinical and tumor information. Hum Mutat 28(5):477–485CrossRefPubMed

85.

Tommasi S, Pilato B, Pinto R et al (2008) Molecular and in silico analysis of BRCA1 and BRCA2 variants. Mutat Res 644(1–2):64–70PubMed

86.

Spearman AD, Sweet K, Zhou XP, McLennan J, Couch FJ, Toland AE (2008) Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance. J Clin Oncol 26(33):5393–5400CrossRefPubMed

87.

Lovelock PK, Healey S, Au W et al (2006) Genetic, functional, and histopathological evaluation of two C-terminal BRCA1 missense variants. J Med Genet 43(1):74–83CrossRefPubMed

88.

Consortium BCL (1997) Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349(9064):1505–1510CrossRef

89.

Adem C, Reynolds C, Soderberg CL et al (2003) Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 97(1):1–11CrossRefPubMed

90.

Hwang ES, McLennan JL, Moore DH, Crawford BB, Esserman LJ, Ziegler JL (2007) Ductal carcinoma in situ in BRCA mutation carriers. J Clin Oncol 25(6):642–647CrossRefPubMed

Titel: The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers
verfasst von: Ana Cristina Vargas
Leonard Da Silva
Sunil R. Lakhani
Publikationsdatum: 01.12.2010
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 4/2010
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-010-9362-5

Springer Medizin

The contribution of breast cancer pathology to statistical models to predict mutation risk in BRCA carriers

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Papillary thyroid cancer in a patient with MUTYH-associated polyposis (MAP)

A novel mutation of the Succinate Dehydrogenase B Gene in a Korean Family with Pheochromocytoma

Clinical and molecular characterization of Brazilian families with von Hippel-Lindau disease: a need for delineating genotype-phenotype correlation

Report of the Combined Meeting of the International Society for Gastrointestinal Hereditary Tumours, the Human Variome Project and the National Cancer Institute Colon Cancer Family Registry, Duesseldorf, Germany, 24 June 2009

Hereditary predisposition rather than environmental factor are likely to explain the familial link between uveal melanoma and other cancers

Magnetic resonance colonography for colorectal cancer screening in patients with Lynch syndrome gene mutation

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie